Skip to main content
World Today News
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology
Menu
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology
Morocco Lags Ethiopia in Pharma Hub Race Over WHO Level 3 Gap, Skills, R&D

Morocco Lags Ethiopia in Pharma Hub Race Over WHO Level 3 Gap, Skills, R&D

November 20, 2026 World Desk World

Ethiopia's regulator has reached WHO maturity level 3 alongside Egypt, South Africa, Nigeria, Ghana, Rwanda and Senegal.

“We only export a model if it is solid at home,” Hamza Guedira, president of the National Order of Pharmacists, told Telquel.ma.

His warning frames a race now running across Africa: which country becomes the continent’s pharmaceutical manufacturing hub.

The trigger came from Addis Ababa. At the Africa Health Products Manufacturing Exhibition and Conference held in late October, Ethiopia’s Health Vice-Minister Muluken Argaw presented his country as a future continental pharmaceutical center, built on the African Continental Free Trade Area (AfCFTA), regional value chains and regulatory cooperation, Telquel.ma reported. He put the Ethiopian pharmaceutical market above $4 billion by 2030.

Morocco, by contrast, has held the African lead before — and lost it. An industry figure who asked Telquel.ma for anonymity said Morocco long held the reins of the African pharmaceutical industry before ceding that position after “several complications.” The contest is now open, and the deciding variable is not factory floors. It is regulatory paperwork.

The WHO level that unlocks a billion buyers

Ethiopia’s regulator has already reached the World Health Organization’s maturity level 3, alongside Egypt, South Africa, Nigeria, Ghana, Rwanda and Senegal. Morocco has not. Karim El Fellah, an expert in pharmaceutical industry, told Telquel.ma that despite a WHO field mission in December 2025 and the adoption of the reformed medicines code, the evaluation remains under way.

“Without WHO maturity level 3, a Moroccan medicine must go through country-by-country evaluations, especially in Africa, and institutional buyers look at it with more reserve and distrust,” El Fellah told Telquel.ma.

The commercial stakes are enormous. AfCFTA covers more than a billion people, yet Africa produces barely 3% of the medicines it consumes and imports between 70% and 90%, according to figures El Fellah cited. In practice, cross-border sales hinge on mutual recognition between African regulators — and those recognitions tie back to WHO maturity ratings.

What Ethiopia promised in Addis Ababa

Ethiopia’s bid rests on more than ambition. The president of the Ethiopian manufacturers’ association pointed to a dedicated industrial park and a regulator classified at WHO maturity level 3, Telquel.ma reported. The stated ten-year target: vaccines, insulin, oncology medicines and African-sourced active pharmaceutical ingredients.

El Fellah judges the Ethiopian ambition credible “on paper and on the generics side,” while calling vaccines, insulin, oncology and active ingredients “more uncertain” over ten years for lack of skills.

Where Ethiopia fits among Morocco’s rivals, per El Fellah’s mapping:

  • Egypt and South Africa — among the two main pharmaceutical powers of the continent.
  • Morocco — in the leading group.
  • Algeria and Tunisia — generics, with an industry founded on import substitution.
  • Ethiopia, Nigeria and Kenya — new entrants, with Ethiopia’s dedicated industrial zone, Nigeria’s local-manufacturing policy and Kenya’s state strategy.

A solid base, an eroded lead

Morocco’s foundation is real. The industry counts around fifty production units, more than 21 billion dirhams in revenue, roughly 1.5% of GDP and over sixty years of expertise, El Fellah told Telquel.ma. Generic manufacturing has run since the 1990s, and proximity to Europe plus free-trade agreements add weight.

But the numbers soften at the edges. Local production covers “between 60% and 80% of national needs in volume depending on the year and the source” — the Health Minister cited about 70% for 2024. In value terms the share is probably lower, El Fellah noted, because costly innovative medicines, biologics and biosimilars are mostly imported. Only about 10% of Moroccan production is exported.

Generic penetration reached “60% by volume,” Samir Ahid, director general of the AMMPS, said at a Competition Council conference in Marrakech on October 14, calling the industry a “national pride.” That measure is distinct from coverage of national needs.

Four failures behind the lost lead

The anonymous industry source cited by Telquel.ma attributed the lost leadership to four problems: dysfunction at the old Directorate of Pharmacy and Medicines (DMP), since replaced by AMMPS, in granting authorizations; “virtually absent” state support for producing laboratories; weak research-and-development backing; and a shortage of pharmacist-researcher profiles. The industrial result, the source said: most laboratories turned to low-cost generics and imports.

Skills are the second brake. Regulatory affairs, quality and pharmacovigilance are exactly the profiles the WHO evaluation requires, and they take years to train. Having worked at the medicines agency and in a laboratory, El Fellah said such profiles are missing “on both sides.”

The agency must focus on “its core business: evaluating, authorizing, inspecting and monitoring drug safety,” which means giving it “the human resources and the autonomy to do so,” he told Telquel.ma.

The two bids, side by side

Measure Morocco Ethiopia
WHO maturity level 3 Not yet reached; evaluation ongoing Reached; regulator WHO-recognized
Market More than 21 billion dirhams in revenue More than $4 billion expected by 2030
Industrial base About fifty production units Dedicated industrial park

Other industrial gaps weigh on Morocco: biosimilars and biotechnology, weak active-ingredient production, and heavy dependence on imported raw materials, per El Fellah’s account to Telquel.ma.

Finishing WHO evaluation unlocks export potential

The fastest lever, El Fellah argued, is finishing the WHO level 3 evaluation and making it the calendar’s priority: “It is the decision that opens the possibility of export under AfCFTA.” Next come shorter marketing-authorization timelines and priority for Moroccan-made generics in public tenders, a demand from industrialists.

Ahid has announced a draft decree introducing conditional and accelerated marketing authorizations, saying market-access delays must be reduced.

Addis Ababa, Ethiopia’s capital and largest city, counts an estimated 6,287,000 inhabitants as of 2025 and sits at an elevation of 2,355 metres, making it the highest capital city in Africa. Founded in 1886 by Menelik II, Negus of Shewa, around abundant mineral springs, it became the imperial capital in 1889.

Known as “the political capital of Africa,” it hosts the headquarters of the African Union and the United Nations Economic Commission for Africa — a diplomatic weight that gives Ethiopia’s pharmaceutical pitch a continental stage.

The dividing line, as Telquel.ma’s reporting frames it, is one sentence long: Morocco has the industrial fabric; Ethiopia already has WHO level 3. Morocco still has to win its own.

More on this story: Moroccan Pharma Group Laprophan Prices Casablanca IPO at MAD 341 to Fund Polymedic Purchase

More on Morocco: Morocco Commits MAD 30M to Train 300 African Aviation Inspectors via ICAO Program · FIFA Inspectors Begin Morocco Tour for 2030 World Cup as Final Dispute Escalates

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Related reading

  • Filipino Singer Carmelle Wins Inaugural Eurovision Song Contest Asia
  • How a Journey Through Australia and South Korea Redefined My Values and Way of Being

Related

Search:

World Today News

World Today News is your trusted source for global journalism — breaking headlines, in-depth analysis, and reporting from around the world.

Quick Links

  • Privacy Policy
  • About Us
  • Accessibility statement
  • California Privacy Notice (CCPA/CPRA)
  • Contact
  • Cookie Policy
  • Disclaimer
  • DMCA Policy
  • Do not sell my info
  • EDITORIAL TEAM
  • Terms & Conditions

Browse by Location

  • GB
  • NZ
  • US

Connect With Us

© 2026 World Today News. All rights reserved. Your trusted global news source directory.
For contact, advertising, copyright, issues email: [email protected]

Privacy Policy Terms of Service